June 28, 2018 04:30 PM EDT
R&D
Pharma

Bio­gen goes deep in­to biosim­i­lars, slap­ping down $700M for a ma­jor stake in Sam­sung Bioepis

John Carroll

Editor & Founder

Bio­gen $BI­IB was pret­ty care­ful when it al­lied with Sam­sung Bioepis back in 2011 — when George Scan­gos was CEO — tak­ing a small mi­nor­i­ty stake in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times